Lancet J, et al. Lancet Haematol. 2021: The 5-year analysis of Study 301
In this final analysis of the Phase III pivotal trial for Vyxeos Liposomal, the authors present the OS outcomes for the overall ITT population, as well as a breakdown of the results by patient age, cytogentic profile, prior HMA exposure, consolidation therapy, and more.
Prescribing Information can be found at the top of this page. Adverse event reporting is available at the bottom of this page.
Topics: Cytogenetics Safety Vyxeos Liposomal Data